Payment overview · 2025
General Payments
$252.56
13 reported records · 9 companies
Healthcare provider profile · identity verified
Lora Ann Siegle, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COUNCIL GROVE, KS · NPI 1407815376
Verified facts
What the public records show
CMS Open Payments records show Lora Ann Siegle, M.D. received $252.56 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.90 | 24.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.38 | 23.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.83 | 9.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.99 | 8.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.49 | 8.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.06 | 7.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.76 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.74 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.41 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.56 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $61.90 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $61.90 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $61.90 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.38 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 98 |
| Lisinopril | Lisinopril | 477 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 395 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 66 |
| Omeprazole | Omeprazole | 334 | 60 |
| Gabapentin | Gabapentin | 325 | 58 |
| Furosemide | Furosemide | 317 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 309 | 50 |
| Losartan Potassium | Losartan Potassium | 293 | 48 |
| Potassium Chloride | Potassium Chloride | 274 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 41 |
| Metformin Hcl | Metformin Hcl | 241 | 44 |
| Simvastatin | Simvastatin | 232 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 39 |
| Celecoxib | Celecoxib | 201 | 37 |
| Atenolol | Atenolol | 186 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 28 |
| Tramadol Hcl | Tramadol Hcl | 181 | 42 |
| Buspirone Hcl | Buspirone Hcl | 177 | 30 |
| Alendronate Sodium | Alendronate Sodium | 168 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 24 |
| Warfarin Sodium | Warfarin Sodium | 125 | 17 |
| Meloxicam | Meloxicam | 124 | 25 |
| Spironolactone | Spironolactone | 123 | 24 |
| Famotidine | Famotidine | 122 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 22 |
| Sertraline Hcl | Sertraline Hcl | 119 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 117 | 14 |
| Allopurinol | Allopurinol | 114 | 19 |
| Eliquis | Apixaban | 108 | 13 |
| Trazodone Hcl | Trazodone Hcl | 104 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 11 |
| Donepezil Hcl | Donepezil Hcl | 67 | suppressed |
| Anastrozole | Anastrozole | 63 | suppressed |
| Carvedilol | Carvedilol | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 22 |
| Lorazepam | Lorazepam | 52 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 35 |
| Cephalexin | Cephalexin | 46 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 13 |
| Montelukast Sodium | Montelukast Sodium | 46 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 18 |
| Fentanyl | Fentanyl | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 41 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 21 |
| Estradiol | Estradiol | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Prednisone | Prednisone | 29 | 17 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Briviact | Brivaracetam | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Lactulose | Lactulose | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.56 · 13 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, EVENITY, Flexitouch Plus, INGREZZA, JARDIANCE, Nimbl, Omnipod, PREVNAR 20, VRAYLAR, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error